Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects.
about
Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteinsA synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibitionA peptide & peptide nucleic acid synthesis technology for transporter molecules and theranostics--the SPPS.Transforming growth factor beta and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection.Comparison of the specificities of IgG, IgG-subclass, IgA and IgM reactivities in African and European HIV-infected individuals with an HIV-1 clade C proteome-based arrayPhylogeny-directed search for murine leukemia virus-like retroviruses in vertebrate genomes and in patients suffering from myalgic encephalomyelitis/chronic fatigue syndrome and prostate cancerNo evidence for xenotropic murine leukemia-related virus infection in Sweden using internally controlled multiepitope suspension array serology.Variants selected by treatment of human immunodeficiency virus-infected cells with an immunotoxin.Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infectionAutologous antibody response against the principal neutralizing domain of human immunodeficiency virus type 1 isolated from infected humansStrain-specific neutralizing determinant in the transmembrane protein of simian immunodeficiency virus.Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategiesHIV-neutralizing antibodies: epitope identification and significance for future vaccine.Peptide component vaccine engineering: targeting the AIDS virus.Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibodyThree-dimensional structure and antigenicity of transmembrane-protein peptides of the human immunodeficiency virus type 1. Effects of a neutralization-escape substitution.Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro.Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzeesThe site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitopeInhibition of lymphoproliferation by a synthetic peptide with sequence identity to gp41 of human immunodeficiency virus type 1Immunobiology of the HIV envelope.Delayed infection after immunization with a peptide from the transmembrane glycoprotein of the feline immunodeficiency virus.Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.Identification of a potent synthetic HIV1 immunogen compromising gag-P24 tandem T- and B-cell epitopes.Affinity of anti-GP41 antibody in patients infected with human immunodeficiency virus type 1.Seroepidemiology of human retroviruses in Ogun State of Nigeria.
P2860
Q24675546-D17A8B8B-39BB-4E3D-902C-3E1E4E9A84C2Q27617901-C9F5DFB5-EB39-4DB5-A438-6A5636B003A8Q28317348-8BDC5D29-E75B-4C49-8BF9-07F0A9C7E0A1Q33628437-0C430B26-03A3-44EB-A187-65DDB615B443Q33864034-A4460F14-1A6F-4891-8B6B-7EA024A54A41Q35057791-5F894D6E-3D33-4B58-80EE-80B3F74813A8Q35692325-13145480-E1E3-40EC-8718-2FB5E5122DDAQ36191612-D99CA60C-E2FD-40E1-A963-E3DFE90EB767Q36353458-A2F6B154-09D1-4399-95C3-48ECF32A50F1Q36423897-BB91AF3D-854E-400D-86AB-34372F579EE5Q36644253-B76FDE15-2C32-479F-B03D-4CDD4DA5B308Q36684349-8D0D733D-7BC4-46E3-B89A-2946B39E45A0Q36690394-8E2B29FC-4FEE-4216-A806-C088B1A6444BQ36708990-1891EEC0-1559-437D-952F-FC721E791BE5Q36708999-5434A2B7-3C67-463B-87C2-6A502CE81E78Q36782627-698DD15A-1D17-4F04-B9E2-CA18C8C3EA19Q36783109-C4E38C03-E3FD-4168-8FD8-29934476672AQ36793253-D9A2A0C6-6315-485F-8A46-041D7B24552AQ36797252-167FC3E5-6F05-445A-9DD0-35BFA2CDCDA3Q36800188-F5A38531-C459-4AA9-B4FD-A79D11ED68E5Q36809662-8B515578-345F-453C-ACCC-CF827FEEED15Q36829695-34179E86-765D-40D5-B16D-72BE85EF5E06Q38705312-D0DA180C-2B14-4CC9-93CF-8D12CA87A652Q39577967-0161BF57-DDF8-41ED-BCC7-F0D45CDC0FD9Q40106699-686DD5EC-5F85-4E4D-991B-9EE38F583FEFQ41979694-D92C2E5C-8134-471C-8A92-551812163795Q45774505-B05B7FE0-0F74-4CE7-B8FA-750DB3013B27Q46589717-20356036-8115-4936-ADA2-57A1B2F2A428
P2860
Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects.
description
1988 nî lūn-bûn
@nan
1988 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Presence of antibodies to a pu ...... h among HIV-positive subjects.
@ast
Presence of antibodies to a pu ...... h among HIV-positive subjects.
@en
type
label
Presence of antibodies to a pu ...... h among HIV-positive subjects.
@ast
Presence of antibodies to a pu ...... h among HIV-positive subjects.
@en
prefLabel
Presence of antibodies to a pu ...... h among HIV-positive subjects.
@ast
Presence of antibodies to a pu ...... h among HIV-positive subjects.
@en
P2860
P356
P1476
Presence of antibodies to a pu ...... h among HIV-positive subjects.
@en
P2093
P2860
P304
P356
10.1073/PNAS.85.14.5225
P407
P577
1988-07-01T00:00:00Z